Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products

Merck has gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products.

Previous post French stocks are pressuring widely held equities indexes. Should you buy the dip?
Next post FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections